Synovitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for synovitis. 20 active patents protecting 2 drugs from 1+ originators. First major cliff: 2032. Daily refresh.

2
Approved drugs
20
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators in Synovitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Merck/Upjohn) 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating synovitis. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
30
4
32
4
33
4
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Indocin Sr
INDOMETHACIN
 — 6 56 — 2030-04-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12133914 Cortef method of use 75 2043-02-23
11904046 Cortef method of use 75 2043-02-23
9089471 Indocin Sr method of use 68 2030-04-23
9089471 Indocin Sr method of use 68 2030-04-23
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19
9675559 Cortef method of use 62 2033-01-10
9675559 Cortef method of use 62 2033-01-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8992982 Indocin Sr formulation 48 2030-04-23
8992982 Indocin Sr formulation 48 2030-04-23
8734847 Indocin Sr formulation 53 2030-04-23
8734847 Indocin Sr formulation 53 2030-04-23
9649280 Cortef method of use 62 2034-05-12
9649280 Cortef method of use 62 2034-05-12
9649280 Cortef method of use 62 2034-05-12
9649280 Cortef method of use 62 2034-05-12
9675559 Cortef method of use 62 2033-01-10
9675559 Cortef method of use 62 2033-01-10

Related